Novartis Buying Regulus In Up To $1.7B Kidney Drug Deal

Covington & Burling LLP-advised Novartis AG said Wednesday it has agreed to acquire Latham & Watkins LLP-guided Regulus Therapeutics Inc. for up to $1.7 billion in a deal that strengthens the...

Already a subscriber? Click here to view full article